Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.59 |
| ▸ | BRD2 | P25440 | 2/20 | 0.59 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524622 | 0.80 | AR (0.71) | BRD4BRD2ARBRD3 | |
| SCHEMBL5432056 | 0.79 | PTGS2 (0.73) | BRD4BRD2 | |
| SCHEMBL8300240 | 0.79 | BRD4 (0.70) | BRD4BRD2MLYCDCREBBPBRD3 | |
| SCHEMBL15815847 | 0.77 | BRD4 (0.73) | BRD4CREBBP | |
| SCHEMBL22524612 | 0.76 | BRD4 (0.50) | BRD4BRD2ARCREBBPBRD3 | |
| SCHEMBL15994968 | 0.76 | ATAD2 (0.52) | BRD4BRD2ARCREBBPBRD3 | |
| SCHEMBL12362813 | 0.76 | BRD4 (0.66) | BRD4BRD2MLYCDCREBBPERN1 | |
| SCHEMBL1772573 | 0.76 | BRD4 (0.66) | BRD4BRD2MLYCDCREBBPBRD3 | |
| SCHEMBL16404607 | 0.76 | BRD4 (0.66) | BRD4BRD2MLYCD | |
| SCHEMBL14678367 | 0.76 | BRD4 (0.66) | BRD4BRD2MLYCDCREBBPBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |